WUXI XDC

Serial Number 98069930
Registration 7763179
700

Registration Progress

Application Filed
Jul 3, 2023
Under Examination
Jan 30, 2024
Approved for Publication
Dec 5, 2023
Published for Opposition
Dec 5, 2023
Registered
Apr 15, 2025

Trademark Image

WUXI XDC

Basic Information

Serial Number
98069930
Registration Number
7763179
Filing Date
July 3, 2023
Registration Date
April 15, 2025
Published for Opposition
December 5, 2023
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
Apr 15, 2025
Registration
Registered
Classes
040 042

Rights Holder

WuXi XDC Cayman Inc.

03
Address
Ugland House
PO Box 309
Grand Cayman KY1-1104
KY

Ownership History

WuXi XDC Cayman Inc.

Original Applicant
03
Grand Cayman KY

WuXi XDC Cayman Inc.

Owner at Publication
03
Grand Cayman KY

WuXi XDC Cayman Inc.

Original Registrant
03
Grand Cayman KY

Legal Representation

Attorney
Eric Lamb

USPTO Deadlines

Next Deadline
1941 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20250415)
Due Date
April 15, 2031
Grace Period Ends
October 15, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

25 events
Date Code Type Description Documents
Apr 15, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Apr 15, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Mar 25, 2025 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Mar 25, 2025 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Feb 21, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 20, 2025 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Dec 8, 2024 IUAF S USE AMENDMENT FILED Loading...
Feb 20, 2025 EX2G S SOU EXTENSION 2 GRANTED Loading...
Dec 8, 2024 EXT2 S SOU EXTENSION 2 FILED Loading...
Feb 20, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Dec 8, 2024 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Dec 8, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 24, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 18, 2024 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jul 18, 2024 EXT1 S SOU EXTENSION 1 FILED Loading...
Jul 18, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jan 30, 2024 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Dec 5, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Dec 5, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Nov 15, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Nov 1, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Oct 31, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 4, 2023 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Aug 3, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 6, 2023 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 040
Custom assembling of materials for others; custom manufacturing of pharmaceuticals; custom manufacturing of drug conjugates; custom production of pharmaceuticals; custom production of biological preparations; custom manufacturing of Antibody-drug Conjugates; custom manufacturing of chemical reagents; custom manufacturing of pharmaceutical preparations; custom manufacturing of biomedical preparations; custom manufacture of drug conjugates; processing of pharmaceutical preparations; processing or treating of chemical reagents; processing of antibody drugs; custom manufacturing of Antibody drugs; processing of biomedical preparations; processing of biotechnology drug
First Use Anywhere: Mar 9, 2023
First Use in Commerce: Mar 9, 2023
Class 042
Development of products for others in the field of pharmaceuticals; pharmaceutical drug development services; research and development of new products in the field of pharmaceuticals; biochemical research and development; custom design and development of chemical reagent antibodies and conjugate antibodies; research and development in the pharmaceutical, biomedicine and biotechnology fields; research and development of antibodies; research and development of conjugated antibodies; biomedical research services; development of pharmaceutical preparations and medicines; research and development of antibody-drug conjugates; research and development of drug conjugates; preclinical research and evaluation of new drugs; consulting services in the field of technology development; research and development of new products for others; scientific research and development
First Use Anywhere: Mar 9, 2023
First Use in Commerce: Mar 9, 2023

Additional Information

Design Mark
The mark consists of the stylized wording "WuXi XDC", with "XDC" partially inside an incomplete oval outline that intersects with another incomplete oval outline.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
040 042